PSU6 Cost-Effectiveness Analysis of Treatment for Rectal Cancer Following Clinical Complete Response  by Rickles, A.S. et al.
rating the videolaparoscopy technique into SUS. Survey about the number of hos-
pitalization and expenditures related to bariatric surgeries effectuated in Brazil in
the period between 2008 and 2012. METHODS: Search, analysis and critical scien-
tific literature usage based on Medline, Pesquisa Saúde and Rebrats (The Brazilian
Network for Health Technology Assessment). A priority was attributed to Brazilian
studies and studies financed by Department of Science and Technology (DECIT) of
the Ministry of Health of Brazil. Data acquisition of expenditures related to bariatric
surgery in the database of the IT Department of SUS (DATASUS). RESULTS: There
have been no observable differences between laparotomical and laparoscopical
methods in such terms as mortality and weight loss. But there have been signifi-
cant differences in the quality of life of the patient and internalization time. The
studies financed by DECIT show that the cost of the surgery varies according to the
access route. The average expenditure for videolaparoscopy was US$12,448.00
compared to US$4,911.00 for the conventional surgery. Data of DATASUS indicates
that the number of hospitalization for bariatric surgery paid by SUS was 16.785. In
this period an increase of more than 68% was observed. The aggregate value of the
expenditure in this field was US$44,116,330.031 for these years. CONCLUSIONS:
The results show that the number of bariatric surgery has increased significantly in
the last years. Therefore it’s necessary to conduct a cost-benefit analysis in the
standpoint of the SUS. This analysis should consider the implications to the quality
of live of patients when evaluating videolaparoscopy bariatric surgery way.
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OBJECTIVES: Total mesorectal excision (TME) in combination with neoadjuvant
chemoradiation (CRT) therapy is the mainstay of rectal cancer treatment today.
With the standard implementation of CRT, however, 15-30% of patients will have a
complete response to therapy without any evidence of residual cancer prior to
surgery. Current standard of care remains to be subsequent surgery along with the
associated risks of a stoma and operative morbidity. Some researchers challenge
the current trends and suggest that these patients can be closely observed rather
than undergo surgery. Using decision analysis modeling we sought to determine
the most cost-effective therapy for patients with rectal cancer who have clinical
complete response (cCR): observation, local resection, or TME. METHODS: An ex-
tensive literature review was performed to determine the event rates, utilities and
costs. Expert opinion was used when there were gaps in the literature. Sensitivity
analysis was performed to determine which variables had the largest influence on
treatment decision. RESULTS: A non-operative approach dominated both local
excision and TME for a cost-effective treatment. Observation without surgery pro-
vided 0.16 additional QALYs over a 5-year period when compared to local excision
and was over $3,000 cheaper. Choosing to observe the patient saved nearly $17,000
compared to TME and added an additional 0.96 QALYs over 5 years. On sensitivity
analysis the probability of a local or distant recurrence when choosing to observe
the patient had the largest effect on the outcome, with a threshold of greater than
12% risk of local or distant recurrence changing the preferred decision to perform
local excision. CONCLUSIONS: Rectal cancer patients with clinical complete re-
sponse often undergo unnecessary and costly surgery. This cost-effectiveness
model shows that choosing to observe patients with clinical complete response is
both cheaper and more effective than surgical intervention for this unique patient
population.
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OBJECTIVES: To evaluate the prognostic factos of secondary hip replacement fol-
lowing the primary reduction internal screw fixation of femoral neck fractures.
METHODS: In this retrospective study the data derive from the database of the
Hungarian National Health Insurance Fund Administration. The study includes
patients over 60 years following primary reduction internal screw fixation of fem-
oral neck fracture (S7200) discharged from inpatient care institutions in 2000. Dur-
ing the 8 years follow up period the data of secondary hip replacement were re-
corded. We evaluated the following risk factors: age, sex (male/female), type of
primary femoral neck fracture (extracapsular, intracapsular undisplaced/intraca-
psular displaced), the season of primary treatment (spring, summer, autumn/win-
ter), day of surgery (week-day/weekend), surgical delay (6-12h, 12-24h, 24h/ 0-6h)
and the absence or presence of comorbidities. The effects of prognostic factors
were evaluated by Cox proportional hazard regression analysis (HR, 95 % CI, p).
RESULTS: A total of 2784 patients with primary reduction internal screw fixation
met the inclusion criteria. In the follow up period 6.82 % (190 cases) of patients
underwent secondary hip replacement, mainly due to osteonecrosis, nonunion
and coxarthrosis. Significant correlation can be shown between suffering second-
ary hip replacement and the age (year, HR0.968, CI:0.951-0.986), the type of frac-
ture (intracapsular undisplaced vs. displaced, HR0.395, CI:0.260-0.601) and the
season of primary surgical intervention (fall vs. winter, HR0.505, CI:0.336-0.760
spring vs. winter, HR0.626, CI:0.429-0.914 summer vs. winter, HR0.613,
CI:0.415-0.906). CONCLUSIONS: The role of age and fracture displacement are well-
known as a risk factors in a literature, but the impact of winter season of primary
osteosynthesis is unknown. In the future this result should be further investigated
in the context of seasonal changes in vitamin D level and bone remodeling, focus-
ing on decreasing the secondary treatment with high burden after femoral neck
fractures with reduction internal fixation.
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OBJECTIVES: Surgical Site Infection (SSIs) is the most frequent type of hospital-
acquired infection, accounting for more than (37%). The prevalence of hospital-
acquired infection in Spain is 7.8%, where SSI account for 19%. For appendectomy
procedures, the SSI rate of 4.9% is reported. SSI increases the patient’s risk of
morbidity and mortality, prolongs hospital stay by more than a week, and worsens
the overall patient quality of life. Moreover, the risk of SSI has increased recently
due to multiple comorbidities. In addition, SSI is becoming more treatment-resis-
tant than ever. The aim of this study was to analyze the economic consequences of
using antibacterial sutures in appendectomy procedures in Spain. METHODS: A
dynamic excel-based decision-analytic model was developed. Published literature
reviews were used to estimate the three key variables: SSI reduction using antibac-
terial sutures (55%7) compared to standard sutured, prolonged length of hospital
stay due to SSI (7.7 days), and the cost of hospital stay per day (2,057€). The rate of
readmission due to persistent infection was used (18%), which was estimated as
costs 2,166€, and it was added to the prior amount to calculate total costs of infec-
tion. Country input data for the model were reported as the number of appendec-
tomy procedures performed per year (34,500). The list price at which regular and
antibacterial sutures were purchased was also collected. A two-way sensitivity
analysis was conducted, with two variables being the infection rate and suture
price. RESULTS: Antibacterial sutures were found to be 14% more expensive; how-
ever, allowing a 56% of hospital cost avoidance. This may have an impact of
4,970,273€ in annual savings in Spain. CONCLUSIONS: This analysis presents new
evidence of support of the use of antibacterial sutures by demonstrating that it
could reduce the SSI rate, and could allow cost-savings compared to standard
sutures, among other benefits.
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OBJECTIVES: No multicenter studies currently assess the incremental costs of au-
togenous bone graft harvest (autograft) in foot and ankle procedures. This study
applied conservatively estimated incremental costs of autograft (with and without
bone graft supplements/enhancers) using an interactive budgetary impact model
comparing costs and cost offsets of an orthobiologic bone graft substitute (-TCP
with recombinant human platelet-derived growth factor-BB [rhPDGF-BB]) in foot
and ankle fusion procedures. METHODS: A Canadian hospital-based budget im-
pact model was developed utilizing International Society of Pharmacoeconomics
and Outcomes Research (ISPOR) guidelines. Clinical and health economic litera-
ture, data from a 434-patient randomized control trial and data from a panel of ten
experienced orthopaedic surgeons provided estimates of medical resource utiliza-
tion and associated hospital costs. Model parameters were confirmed by six indi-
viduals representing 15 Canadian hospitals. RESULTS:Autograft carries incremen-
tal costs related to operating suite time (37.9 17.0 minutes for an iliac crest donor
site and 22.1  21.6 minutes for local donor sites), recovery room time (25.0  12.3
minutes for iliac and 3.5  9.4 minutes for local), and donor site complications.
Conservative base case incremental costs were $1,601(CAD) for iliac crest and $755
(CAD) for local sites. Complications at the harvest site contributed an additional
base case cost of $414 for iliac crest and $182 for local sites. Use of an orthobiologic
bone graft substitute had higher acquisition costs, but yielded per-case and annu-
alized cost savings ($34 and $2,454, respectively, base case) by eliminating incre-
mental costs, graft harvest complications, and patient pain reported for autograft
harvest during clinical trial. CONCLUSIONS: The gold standard of harvesting au-
togenous bone graft as an adjunct to foot and ankle fusion surgery is associated
with significant health care costs. The use of -TCP with rhPDGF-BB eliminated
variable, incremental hospital costs associated with bone graft harvesting and
treating related complications.
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OBJECTIVES: Chronic kidney disease (CKD) and end-stage kidney disease are well-
established risk factors for early mortality and morbididy in patients with coronary
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